Sanofi Showcases Long-Term Benefits Of Dupixent For Severe Asthma
Another Boost For Blockbuster
Executive Summary
While many analysts have been focusing on the growth potential of Regeneron-partnered Dupixent in atopic dermatitis, the French giant has been highlighting the biologic's benefits for asthma with three-year data presented at the ERS meeting.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Sanofi Impacted By COVID 19 Headwinds, But Dupixent Powers Forward
Company keeps on track on for 2020 earnings target despite pandemic's hit to general medicines and vaccines sales.
New China Approvals Include Amgen, Sanofi, Hengrui Drugs, Innovent Biosimilar
Several high-profile products including Dupixent gain approvals in China.